REGN5458 (BCMAxCD3 Bispecific)
Relapsed/Refractory Multiple Myeloma
Sponsor Regeneron
500 Enrollment Target
85 Trial Sites
5 Countries
November 2027 Est. Completion
About This Trial
Bispecific antibody redirecting T-cells to BCMA-expressing myeloma cells.
Primary Endpoints
- Overall survival
- Complete response rate
Latest Update
February 2026
Phase 2 showed 63% overall response rate. Registrational Phase 3 fully enrolled ahead of schedule.